Trial
NCT01126749
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Eisai Inc.
Collaborators
PharmaBio Development Inc.
Condition
Bladder Cancer
Intervention
Gemcitabine
Why stopped
Study was terminated as per sponsor's decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-28